We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+8.97%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$425M
AUM Growth
-$23.3M
(-5.2%)
Cap. Flow
+$28.2M
Cap. Flow
% of AUM
6.64%
Top 10 Holdings %
Top 10 Hldgs %
49.03%
Holding
60
New
17
Increased
11
Reduced
11
Closed
10
Top Buys
| 1 |
Kura Oncology
KURA
|
+$8.7M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$6.55M |
| 3 |
Gyre Therapeutics
GYRE
|
+$6.09M |
| 4 |
Celldex Therapeutics
CLDX
|
+$5.74M |
| 5 |
Viridian Therapeutics
VRDN
|
+$5.62M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
+$12.9M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$10.6M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$9.61M |
| 4 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
+$9.24M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$8.51M |
Sector Composition
| 1 | Healthcare | 77.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
STSA
26
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $5.14M | 1.21% |
904,225
+704,225
| +352% | +$4.27M |
|
27
MoonLake Immunotherapeutics
MLTX
$1.64B
| $5.12M | 1.2% |
500,000
| – | – |
|
28
BioCryst Pharmaceuticals
BCRX
$2.36B
| $5.08M | 1.2% |
500,000
-400,000
| -44% | -$4.12M |
|
|
EPIX
29
DELISTED
ESSA Pharma
EPIX
| $5.08M | 1.19% |
+175,000
| New | +$4.07M |
|
|
30
Gyre Therapeutics
GYRE
$675M
| $5.04M | 1.18% |
+133,333
| New | +$6.09M |
|
|
31
Viridian Therapeutics
VRDN
$1.99B
| $5.01M | 1.18% |
+300,000
| New | +$5.62M |
|
32
Nuvation Bio
NUVB
$2.02B
| $4.96M | 1.17% |
+500,000
| New | +$5.59M |
|
33
Curis
CRIS
$9.02M
| $4.81M | 1.13% |
1,063
| – | – |
|
|
BCYC
34
Bicycle Therapeutics
BCYC
$294M
| $4.48M | 1.05% |
+150,000
| New | +$3.87M |
|
|
KYNB
35
Kyntra Bio
KYNB
$29.3M
| $4.34M | 1.02% |
+5,000
| New | +$5.32M |
|
36
Immunic
IMUX
$207M
| $4.22M | 0.99% |
26,500
| – | – |
|
37
Immunovant
IMVT
$8.27B
| $4.01M | 0.94% |
250,000
-50,000
| -17% | -$1.32M |
|
|
SRRA
38
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.45M | 0.81% |
200,000
| – | – |
|
39
Novavax
NVAX
$1.35B
| $3.17M | 0.75% |
+17,500
| New | +$3.49M |
|
|
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
| $2.62M | 0.62% |
265,000
-335,000
| -56% | -$5.19M |
|
|
KDMN
41
DELISTED
Kadmon Holdings, Inc.
KDMN
| $2.33M | 0.55% |
+600,000
| New | +$2.75M |
|
|
SAGE
42
DELISTED
Sage Therapeutics
SAGE
| $2.25M | 0.53% |
+30,000
| New | +$2.46M |
|
|
CTIC
43
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $2.18M | 0.51% |
750,000
| – | – |
|
44
Precision BioSciences
DTIL
$203M
| $2.07M | 0.49% |
+6,667
| New | +$2.33M |
|
|
45
PUT
Celldex Therapeutics
CLDX
$2.77B
| $2.06M | 0.48% |
+100,000
| New | +$2.3M |
|
|
CMRX
46
DELISTED
Chimerix, Inc.
CMRX
| $1.93M | 0.45% |
+200,000
| New | +$1.84M |
|
|
CASI
47
DELISTED
CASI Pharmaceuticals
CASI
| $1.56M | 0.37% |
+65,000
| New | +$1.83M |
|
48
Aptevo Therapeutics
APVO
$5.91M
| – | – |
0
| – | – |
|
|
OTIC
49
DELISTED
Otonomy, Inc.
OTIC
| $1.15M | 0.27% |
450,000
+250,000
| +125% | +$1.02M |
|
50
PUT
Korro Bio
KRRO
$177M
| $950K | 0.22% |
+2,000
| New | +$3.89M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2021 Portfolio in Review
As of Q1 2021, Ghost Tree Capital held 60 positions worth $425M, down 5.2% from $449M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Ghost Tree Capital deployed $28.2M of net new capital in Q1 2021, opening 17 new positions and adding to 11 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 30,000 shares worth $6.63M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 83% a quarter earlier.
On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $10.6M trimmed.
- Ghost Tree Capital's largest Q1 2021 buy was iShares Russell 2000 ETF: 30,000 shares worth $6.63M.
- Ghost Tree Capital added most to Kura Oncology in Q1 2021, an estimated $8.7M increase.
- Ghost Tree Capital's biggest Q1 2021 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $10.6M.
- Ghost Tree Capital fully exited Travere Therapeutics in Q1 2021, selling an estimated $12.9M.
- Ghost Tree Capital's ten largest holdings make up 49% of its $425M portfolio in Q1 2021.
- Ghost Tree Capital opened 17 new positions and closed 10 in Q1 2021.
- Ghost Tree Capital's portfolio value fell 5.2% quarter-over-quarter to $425M.
Based on Ghost Tree Capital's 13F filing for Q1 2021, filed 14 May 2021.